Lung & Respiratory Disease Clinical Trials Update: Week 32, 2026

Published August 7, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

ARrest RESpiraTory Failure From PNEUMONIA

This Phase 3 trial tested an inhaled combination treatment for patients hospitalized with pneumonia who had low oxygen levels. The treatment aimed to prevent acute respiratory failure, a serious complication that can lead to longer hospital stays and more intensive care. Conducted at multiple locations across the United States, the study’s results are now available, offering new insights into managing pneumonia and potentially reducing the risks associated with respiratory failure in these patients.

Airway Dysfunction, Occlusions and Remodeling: COPD Patients and Mepolizumab

This Phase 4 trial explored the use of mepolizumab, an injectable antibody treatment, in adults living with chronic obstructive pulmonary disease (COPD). The goal was to see if mepolizumab could improve lung function by reducing mucus buildup and airway blockages. Over 48 weeks, patients had multiple visits for imaging and breathing tests, which could help provide new treatment options to improve breathing and quality of life for people with COPD.

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

This Phase 4 study is investigating whether dupilumab, a biologic medicine, can improve mucociliary clearance in adults with moderate to severe asthma. Mucociliary clearance is the process that helps clear mucus and debris from the lungs, and improving it may help control asthma symptoms better. The trial is recruiting participants in the United States and plans to enroll 30 adults, aiming to provide more information on how this treatment could help manage asthma.

Vital-signs-integrated Patient-assisted Intravenous Opioid Analgesia

This Phase 2 trial tested a new system that combines patient-controlled intravenous opioid pain relief with continuous monitoring of vital signs to prevent respiratory depression after surgery. Respiratory depression is a dangerous slowing of breathing that can happen with opioid use. Conducted in Singapore, this study focused on improving patient safety during pain management by detecting and preventing breathing problems early.

Infants With Severe Acute Respiratory Distress Syndrome: The Prone Trial

This trial is studying whether placing infants with severe acute respiratory distress syndrome (ARDS) in a prone position, lying on their stomachs, helps improve oxygen levels and lung function compared to lying on their backs. The study is recruiting infants in Austria who are mechanically ventilated and have received surfactant therapy. Results may help guide better care techniques for infants facing serious lung injury.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.